Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

604 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy.
Linares J, Sallent-Aragay A, Badia-Ramentol J, Recort-Bascuas A, Méndez A, Manero-Rupérez N, Re DL, Rivas EI, Guiu M, Zwick M, Iglesias M, Martinez-Ciarpaglini C, Tarazona N, Varese M, Hernando-Momblona X, Cañellas-Socias A, Orrillo M, Garrido M, Saoudi N, Elez E, Navarro P, Tabernero J, Gomis RR, Batlle E, Pisonero J, Cervantes A, Montagut C, Calon A. Linares J, et al. Among authors: cervantes a. Nat Commun. 2023 Feb 10;14(1):746. doi: 10.1038/s41467-023-36334-1. Nat Commun. 2023. PMID: 36765091 Free PMC article.
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Tabernero J, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, Van Laethem JL, Soulié P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de Gramont A. Tabernero J, et al. Among authors: cervantes a. J Clin Oncol. 2007 Nov 20;25(33):5225-32. doi: 10.1200/JCO.2007.13.2183. J Clin Oncol. 2007. PMID: 18024868 Clinical Trial.
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.
Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, Macarulla T, Rodriguez-Braun E, Eugenia Vega-Villegas M, Senger S, Ramos FJ, Roselló S, Celik I, Stroh C, Baselga J, Ciardiello F. Tabernero J, et al. Among authors: cervantes a. J Clin Oncol. 2010 Mar 1;28(7):1181-9. doi: 10.1200/JCO.2009.22.6043. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100964 Clinical Trial.
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics.
Macarulla T, Cervantes A, Elez E, Rodríguez-Braun E, Baselga J, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton O, Fingert H, Tabernero J. Macarulla T, et al. Among authors: cervantes a. Mol Cancer Ther. 2010 Oct;9(10):2844-52. doi: 10.1158/1535-7163.MCT-10-0299. Epub 2010 Aug 19. Mol Cancer Ther. 2010. PMID: 20724522 Clinical Trial.
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J. Baselga J, et al. Among authors: cervantes a. Clin Cancer Res. 2010 Oct 1;16(19):4876-83. doi: 10.1158/1078-0432.CCR-10-0748. Epub 2010 Aug 30. Clin Cancer Res. 2010. PMID: 20805299 Clinical Trial.
Treatment recommendations for metastatic colorectal cancer.
Aranda E, Abad A, Carrato A, Cervantes A, García-Foncillas J, García Alfonso P, García Carbonero R, Gómez España A, Tabernero JM, Díaz-Rubio E. Aranda E, et al. Among authors: cervantes a. Clin Transl Oncol. 2011 Mar;13(3):162-78. doi: 10.1007/s12094-011-0636-7. Clin Transl Oncol. 2011. PMID: 21421461 Review.
A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors.
Tabernero J, Dirix L, Schöffski P, Cervantes A, Lopez-Martin JA, Capdevila J, van Beijsterveldt L, Platero S, Hall B, Yuan Z, Knoblauch R, Zhuang SH. Tabernero J, et al. Among authors: cervantes a. Clin Cancer Res. 2011 Oct 1;17(19):6313-21. doi: 10.1158/1078-0432.CCR-11-1101. Epub 2011 Aug 10. Clin Cancer Res. 2011. PMID: 21831953 Clinical Trial.
Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Roselló S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Maños L, Pérez-Fidalgo JA, Fingert H, Baselga J, Tabernero J. Cervantes A, et al. Clin Cancer Res. 2012 Sep 1;18(17):4764-74. doi: 10.1158/1078-0432.CCR-12-0571. Epub 2012 Jul 2. Clin Cancer Res. 2012. PMID: 22753585 Clinical Trial.
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Reboredo M, Manzano JL, Rivera F, Safont MJ, Montagut C, González E, Benavides M, Marcuello E, Cervantes A, Martínez de Prado P, Fernández-Martos C, Arrivi A, Bando I, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Díaz-Rubio E, et al. Among authors: cervantes a. PLoS One. 2012;7(10):e47345. doi: 10.1371/journal.pone.0047345. Epub 2012 Oct 12. PLoS One. 2012. PMID: 23174912 Free PMC article. Clinical Trial.
604 results